introduction

Dieter A. Wolf Ph.D.

  发布时间: 2016-09-08   信息员:    浏览次数: 30

Dr.Dieter A. Wolf  


Dr. Wolf studied medicine at the University in  Munich, Germany. After postdoctoral work at Harvard Medical School and Stanford  University School of Medicine, he joined the Department of Cancer Cell Biology  at Harvard as an Assistant Professor in 1998. In 2007, Dr. Wolf moved to Sanford-Burnham Medical Research Institute as Professor and  Director of Proteomics. In 2015, Dr. Wolf was recruited to Xiamen University’s  School of Pharmaceutical Sciences as a Foreign 1000 Talents Professor.  


Dr. Wolf’s research focuses on protein quality  control and associated stress response pathways and their utility as cancer drug  targets. Among the most significant achievements were the identification of BTB  proteins as substrate adapters of cullin3-based ubiquitin ligases and studies on  the regulation of cullin-RING ubiquitin ligases by deneddylation. The lab has  also addressed the proteolytic control of the prostate tumor suppressor p27. A  major achievement was the identification of compound SMIP004 as an inhibitor of  27 degradation and an inducer of cancer cell-selective apoptosis in prostate  cancer cells through Unfolded Protein Response signaling downstream of  mitochondrial inhibition.

Proteomic technology employing LC-MS/MS for  comprehensive protein profiling and analysis of the dynamics of protein  complexes has been central to this work. Among the most recent achievements  using proteomicswere the identification of the “translasome“ as a direct  physical link between the protein synthesis and degradation machineries, the  demonstration that CAND1 is a factor controlling the dynamic assembly of  cullin-RING ubiquitin ligases, a systems view of gene expression in response to  oxidative stress, and quantitative profiling of drug effector pathways in  prostate cancer cells. This research also employs network-based and mathematical  modeling approaches.


At Xiamen University, Dr. Wolf’s lab will focus on  castration-resistant prostate cancer - a major health issue in China and beyond  - establishing patient-derived xenograft models, in vivo loss-of-function  screens, and cancer proteomics for the identification of novel drug targets. A  second focus concerns mechanisms controlling protein synthesis, their roles in  cancer, and their potential as novel drug targets.


Wolf, D.A. (2014)  Is reliance on mitochondrial respiration a chink in the armor of  therapy-resistant cancer? Cancer Cell 26, 788-795


Yang C.-C.; Chung, A.; Brill, L.M.; Williams, R.;  Wolf, D.A. (2014) Systems analysis of the prostate tumor suppressor NKX3.1  supports roles in DNA repair and luminal cell differentiation. F1000Research  2014, 3:115


Rico-Bautista, E.; Zhu, W.; Kitada, S.; Ganapathy,  S.; Lau, E.; Krajewski, S.; Ramirez, J.; Bush, J.A.; Yuan, Z.; Wolf, D.A.(2013) Small molecule-induced mitochondrial  disruption directs prostate cancer inhibition via unfolded protein response  signaling. Oncotarget 4, 1212-1229 -


Wu, S..; Zhou, W.; Nhan, T.; Toth J.I.; Petroski,  M.D.; Wolf, D.A. (2013) CAND1 controls in vivo dynamics of the cullin 1-RING  ubiquitin ligase repertoire. Nature Communications 4, 1642


Bauer, F.; Matsuyama, A.; Candiracci, J.; Dieu, M.;  Scheliga, S.; Wolf, D.A.; Yoshida, M.; Hermand, D. (2012) Translational control  of cell division by elongator. Cell Reports 1, 424-433 - This article was cited  here


Lackner, D.H.; Schmidt, M.W.; Wu, S.; Wolf, D.A.,  Bähler, J. (2012) Regulation of transcriptome, translation, and proteome in  response to environmental stress in fission yeast. Genome Biology 13:R25  


Keren-Kaplan, T.; Attali, I., Motamedchaboki, K.;  Davis, B.A.; Tanner, N., Reshef, Y., Laudon, E.; Kolot, M.; Levin-Kravets, O.;  Kleifeld, O.; Glickman, M.; Horazdovsky, B.F.; Wolf, D.A., Prag, G. (2012)  Synthetic biology approach to reconstituting the ubiquitylation cascade in  bacteria. EMBO J., 31, 378 - 390


Rico-Bautista, E.; Yang, C.-C.; Lu, L.; Roth, G.P.;  Wolf, D.A. (2010) Chemical genetics approach to restoring p27Kip1 reveals novel  compounds with antiproliferative activity in prostate cancer cells. BMC Biology  8:153

website:http://dieter-wolf-lab-xmu.strikingly.com/





Copyright©2011 School of Pharmaceutical Sciences Xiamen University All Rights Reserved